Scholarlink

<p>Myocardial ischemia–reperfusion injury (MIRI) is a common pathological process following treatment for acute myocardial infarction and other cardiovascular diseases, leading to cardiomyocyte apoptosis and impaired cardiac functional recovery. Engeletin possesses anti-inflammatory, antioxidant and anti-apoptotic pharmacological activities, but its poor water solubility and low bioavailability limit clinical application. In this study, we grafted both synthetic compound 1 and a natural extract–derived compound 2 onto sodium alginate/3-aminopropyltrimethoxysilane to prepare a novel fluorescent, biocompatible composite carrier (1-DASA-2-APTMS@Engeletin). FTIR and XRD confirmed successful fabrication and drug loading, and fluorescence spectroscopy showed a quantum yield of 12.5% at an excitation wavelength of 370 nm. <i>In vitro</i>, a hypoxia–reoxygenation (H/R) model was established in H9c2 cardiomyocytes to assess the protective effects of 1-DASA-2-APTMS@Engeletin. The results demonstrated that this nanoparticle system increased cell viability in a concentration-dependent manner by modulating apoptosis-related gene expression and significantly enhanced Engeletin’s anti-apoptotic effect. This study validates the potential of 1-DASA-2-APTMS@Engeletin as a novel therapeutic agent for MIRI and provides key experimental groundwork for the development of cardioprotective drugs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Porous sodium alginate–organosilane nanocarrier to attenuate apoptosis in hypoxia-reoxygenation H9c2 cardiomyocytes

  • 期刊论文

  • 发表日期：

    2026年5月2日

查看全文
  • Yan Xiang,
  • Zhenyu Cui,
  • Tianxin Geng,
  • Jinlong Zhao

摘要

Myocardial ischemia–reperfusion injury (MIRI) is a common pathological process following treatment for acute myocardial infarction and other cardiovascular diseases, leading to cardiomyocyte apoptosis and impaired cardiac functional recovery. Engeletin possesses anti-inflammatory, antioxidant and anti-apoptotic pharmacological activities, but its poor water solubility and low bioavailability limit clinical application. In this study, we grafted both synthetic compound 1 and a natural extract–derived compound 2 onto sodium alginate/3-aminopropyltrimethoxysilane to prepare a novel fluorescent, biocompatible composite carrier (1-DASA-2-APTMS@Engeletin). FTIR and XRD confirmed successful fabrication and drug loading, and fluorescence spectroscopy showed a quantum yield of 12.5% at an excitation wavelength of 370 nm. In vitro, a hypoxia–reoxygenation (H/R) model was established in H9c2 cardiomyocytes to assess the protective effects of 1-DASA-2-APTMS@Engeletin. The results demonstrated that this nanoparticle system increased cell viability in a concentration-dependent manner by modulating apoptosis-related gene expression and significantly enhanced Engeletin’s anti-apoptotic effect. This study validates the potential of 1-DASA-2-APTMS@Engeletin as a novel therapeutic agent for MIRI and provides key experimental groundwork for the development of cardioprotective drugs.